Equities

Carasent ASA

Carasent ASA

Actions
Health CareHealth Care Providers
  • Price (NOK)18.00
  • Today's Change-0.25 / -1.37%
  • Shares traded37.21k
  • 1 Year change+34.73%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in NOKIncome statement in NOKView more

Year on year Carasent ASA had net income fall from a gain of 31.17m to a loss of 46.45m despite a 24.95% increase in revenues from 195.26m to 243.98m. An increase in the selling, general and administrative costs as a percentage of sales from 65.91% to 75.59% was a component in the falling net income despite rising revenues.
Gross margin82.76%
Net profit margin-4.09%
Operating margin-14.81%
Return on assets-0.86%
Return on equity-0.98%
Return on investment-0.94%
More ▼

Cash flow in NOKView more

In 2023, cash reserves at Carasent ASA fell by 323.39m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 4.47m. In addition the company used 55.53m on investing activities and also paid 263.28m in financing cash flows.
Cash flow per share0.6264
Price/Cash flow per share28.63
Book value per share12.93
Tangible book value per share4.56
More ▼

Balance sheet in NOKView more

Carasent ASA appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio3.94
Quick ratio--
Total debt/total equity0.0487
Total debt/total capital0.0464
More ▼

Growth rates in NOK

Year on year, growth in earnings per share excluding extraordinary items dropped -252.29%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
77.03
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.